Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
JR Richter, TG Martin, R Vij, C Cole, D Atanackovic… - 2016 - ascopubs.org
8005 Background: Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody with
multiple modes of action for killing tumor cells through direct tumor targeting and immune
cell engagement. Here, we report updated data from an ongoing Phase II dose finding study
of ISA monotherapy in patients (pts) with RRMM (NCT01084252). Methods: Pts with RRMM
(≥ 3 lines of anti-MM therapy or refractory to immunomodulatory drugs [IMiDs] and
proteasome inhibitors [PIs]) were randomized to ISA 3 mg/kg Q2W, 10 mg/kg Q2W x 2 cycles …
multiple modes of action for killing tumor cells through direct tumor targeting and immune
cell engagement. Here, we report updated data from an ongoing Phase II dose finding study
of ISA monotherapy in patients (pts) with RRMM (NCT01084252). Methods: Pts with RRMM
(≥ 3 lines of anti-MM therapy or refractory to immunomodulatory drugs [IMiDs] and
proteasome inhibitors [PIs]) were randomized to ISA 3 mg/kg Q2W, 10 mg/kg Q2W x 2 cycles …
以上显示的是最相近的搜索结果。 查看全部搜索结果